{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:29:04Z","timestamp":1789558144274,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.jvca.2025.02.030","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T16:03:36Z","timestamp":1740240216000},"page":"1441-1450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery"],"prefix":"10.1053","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-8439","authenticated-orcid":false,"given":"Jonathan S.","family":"Auerbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alnajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley B.","family":"Gershengorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lamelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daitiara","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar D.","family":"Aljure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanira D.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaro A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge L.","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.02.030_bib0001","doi-asserted-by":"crossref","first-page":"961","DOI":"10.15585\/mmwr.mm6843a2","article-title":"Diabetes prevalence and incidence among Medicare beneficiaries: United States, 2001-2015","volume":"68","author":"Andes","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 1","key":"10.1053\/j.jvca.2025.02.030_bib0002","article-title":"Prevalence and incidence of obesity and diabetes in the United States, 2011-2017","volume":"69","author":"Nielsen","year":"2020","journal-title":"Diabetes"},{"key":"10.1053\/j.jvca.2025.02.030_bib0003","doi-asserted-by":"crossref","first-page":"k1497","DOI":"10.1136\/bmj.k1497","article-title":"Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: Population based study","volume":"362","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"10.1053\/j.jvca.2025.02.030_bib0004","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/0091270011400604","article-title":"SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus","volume":"52","author":"Ghosh","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.jvca.2025.02.030_bib0005","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1053\/j.jvca.2025.02.030_bib0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0007","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12244","article-title":"Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport","volume":"276","author":"Abdul-Ghani","year":"2014","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0008","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2025.02.030_bib0009","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.02.030_bib0010","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0012","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0013","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.030_bib0014","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0015","first-page":"4","volume":"24","author":"McDonagh","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2025.02.030_bib0016","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes"},{"key":"10.1053\/j.jvca.2025.02.030_bib0017","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.jvca.2023.01.041","article-title":"Postcardiac surgery euglycemic diabetic ketoacidosis in patients on sodium-glucose cotransporter 2 inhibitors","volume":"37","author":"Auerbach","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.02.030_bib0018","series-title":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections","year":"2022"},{"key":"10.1053\/j.jvca.2025.02.030_bib0019","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1053\/j.jvca.2025.02.030_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.aace.2020.11.014","article-title":"A case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery","volume":"7","author":"Osafehinti","year":"2020","journal-title":"AACE Clin Case Rep"},{"key":"10.1053\/j.jvca.2025.02.030_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium\u2013glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace","year":"2018","journal-title":"J Pancreat Cancer"},{"key":"10.1053\/j.jvca.2025.02.030_bib0022","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: Pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2025.02.030_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcjd.2022.06.007","article-title":"Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis: Lessons from a case series of 4 patients undergoing coronary artery bypass grafting surgery","author":"Chaudhry","year":"2022","journal-title":"Can J Diabetes"},{"key":"10.1053\/j.jvca.2025.02.030_bib0024","unstructured":"The Society of Thoracic Surgeons National Database. https:\/\/www.sts.org\/registries\/sts-national-database\/adult-cardiac-surgery-database. Retrieved October 20, 2022"},{"key":"10.1053\/j.jvca.2025.02.030_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","article-title":"Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: A systematic review of case reports","volume":"37","author":"Seki","year":"2023","journal-title":"J Anesth"},{"key":"10.1053\/j.jvca.2025.02.030_bib0026","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00540-024-03335-3","article-title":"Incidence of sodium-glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: A prospective cohort study","volume":"38","author":"Seki","year":"2024","journal-title":"J Anesth"},{"key":"10.1053\/j.jvca.2025.02.030_bib0027","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4103\/aca.aca_47_21","article-title":"A retrospective analysis of the incidence, outcome and factors associated with the occurrence of euglycemic ketoacidosis in diabetic patients on sodium glucose co-transporter-2 inhibitors undergoing cardiac surgery","volume":"25","author":"Murugesan","year":"2022","journal-title":"Ann Card Anaesth"},{"key":"10.1053\/j.jvca.2025.02.030_bib0028","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.bja.2023.06.063","article-title":"Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: A single-centre retrospective analysis","volume":"131","author":"Steinhorn","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2025.02.030_bib0029","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1038\/s41598-024-58853-7","article-title":"Missed postoperative metabolic acidosis associated with sodium-glucose transporter 2 inhibitors in cardiac surgery patients: A retrospective analysis","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1053\/j.jvca.2025.02.030_bib0030","article-title":"Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery: The impact of SGLT2 inhibitor use: A retrospective cohort study","author":"Brekke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.02.030_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.828649","article-title":"New diabetic medication sodium-glucose cotransporter-2 inhibitors can induce euglycemic ketoacidosis and mimic surgical diseases: A case report and review of literature","volume":"9","author":"Kietaibl","year":"2022","journal-title":"Front Surg"},{"key":"10.1053\/j.jvca.2025.02.030_bib0032","first-page":"e13665","article-title":"Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: A focused review of pathophysiology","volume":"13","author":"Somagutta","year":"2021","journal-title":"Risk Factors, and Triggers. Cureus"},{"key":"10.1053\/j.jvca.2025.02.030_bib0033","doi-asserted-by":"crossref","first-page":"e01380","DOI":"10.1213\/XAA.0000000000001380","article-title":"Intraoperative diagnosis of sodium-glucose cotransporter 2 inhibitor-associated euglycemic diabetic ketoacidosis: A case report","volume":"15","author":"Seger","year":"2021","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2025.02.030_bib0034","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","article-title":"SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)","volume":"23","author":"Paolisso","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1053\/j.jvca.2025.02.030_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-023-00618-0","article-title":"The use of sodium-glucose cotransporter-2 inhibitors in coronary revascularization: Where are we now? A systematic review","volume":"24","author":"El-Andari","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2025.02.030_bib0036","doi-asserted-by":"crossref","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1053\/j.jvca.2025.02.030_bib0037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0038","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/joim.12244","article-title":"Lowering plasma glucose concentration by inhibiting renal sodium-glucose co-transport","volume":"276","author":"Abdul-Ghani","year":"2014","journal-title":"J Intern Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0039","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.jvca.2025.02.030_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1053\/j.jvca.2025.02.030_bib0041","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0042","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0043","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0044","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2025.02.030_bib0045","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.02.030_bib0046","first-page":"4","volume":"24","author":"McDonagh","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T03:33:31Z","timestamp":1746588811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1053077025001703"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.030","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}